ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)
China · Delayed Price · Currency is CNY 33.20
-1.17 (-3.40%)
Sep 24, 2026, 3:04 PM CST
SHE:300723 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 14,891 | 15,065 | 7,660 | 13,394 | 9,894 | 10,200 | |
Market Cap Growth | -43.79% | 96.66% | -42.81% | 35.38% | -3.00% | 60.89% |
Enterprise Value | 15,633 | 16,527 | 8,774 | 13,988 | 10,650 | 10,763 |
Last Close Price | 33.20 | 33.55 | 17.06 | 29.55 | 22.74 | 23.45 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 68.02 | - | - | 72.55 | 34.04 | 33.23 |
Forward PE | 28.62 | 58.60 | 30.13 | 30.71 | 29.43 | 27.61 |
PS Ratio | 17.72 | 16.16 | 5.28 | 5.35 | 4.34 | 4.64 |
PB Ratio | 7.92 | 10.71 | 3.96 | 5.16 | 4.57 | 5.05 |
P/TBV Ratio | 10.08 | 15.39 | 5.28 | 6.49 | 6.27 | 7.27 |
P/FCF Ratio | 225.25 | - | - | 108.38 | - | - |
P/OCF Ratio | 93.89 | 327.41 | - | 29.24 | 20.81 | 23.28 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 18.61 | 17.73 | 6.05 | 5.59 | 4.67 | 4.89 |
EV/EBITDA Ratio | - | - | - | 36.11 | 29.06 | 35.20 |
EV/EBIT Ratio | - | - | - | 60.99 | 36.15 | 42.00 |
EV/FCF Ratio | 236.47 | - | - | 113.18 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.09 | 1.47 | 0.87 | 0.31 | 0.54 | 0.61 |
Debt / EBITDA Ratio | - | - | - | 1.95 | 2.98 | 3.73 |
Debt / FCF Ratio | 31.05 | - | - | 6.49 | - | - |
Net Debt / Equity Ratio | 0.38 | 1.11 | 0.63 | 0.13 | 0.21 | 0.07 |
Net Debt / EBITDA Ratio | -5.25 | -11.53 | -11.03 | 0.87 | 1.23 | 0.46 |
Net Debt / FCF Ratio | 10.70 | -19.18 | -1.40 | 2.74 | -3.45 | -1.13 |
Asset Turnover | 0.18 | 0.22 | 0.33 | 0.59 | 0.58 | 0.75 |
Inventory Turnover | 1.51 | 1.66 | 1.82 | 1.84 | 2.05 | 2.86 |
Quick Ratio | 1.26 | 0.70 | 0.48 | 0.62 | 0.93 | 1.13 |
Current Ratio | 1.49 | 0.97 | 0.73 | 0.91 | 1.17 | 1.30 |
Return on Equity (ROE) | 11.38% | -20.73% | -25.00% | 6.37% | 12.53% | 16.70% |
Return on Assets (ROA) | -4.27% | -4.84% | -4.16% | 3.37% | 4.71% | 5.45% |
Return on Invested Capital (ROIC) | -12.35% | -10.69% | -9.64% | 5.14% | 9.91% | 12.94% |
Return on Capital Employed (ROCE) | -10.00% | -11.30% | -11.00% | 7.90% | 10.20% | 10.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.48% | -2.24% | -7.05% | 1.38% | 2.94% | 3.01% |
FCF Yield | 0.44% | -0.54% | -11.36% | 0.92% | -1.32% | -1.21% |
Dividend Yield | - | - | - | 0.71% | 0.59% | 0.57% |
Payout Ratio | 37.15% | - | - | 35.77% | 21.88% | 12.90% |
Buyback Yield / Dilution | 0.02% | -0.01% | 0.00% | -4.43% | -1.94% | 2.20% |
Total Shareholder Return | 0.02% | -0.01% | 0.00% | -3.72% | -1.35% | 2.77% |